Ramelteon - Indication, Dosage, Precautions, and Pharmacological Aspects

Overview:

Ramelteon is prescribed for patients with sleep-onset insomnia, which is defined by trouble falling asleep. As of now, it is the only melatonin receptor agonist that is authorized to treat insomnia. It was approved by the United States Food and Drug Administration (USFDA) in 2005.

Drug Group:

Ramelteon belongs to a group of drugs known as melatonin receptor agonists. It functions similarly to melatonin, a hormone produced naturally in the brain and necessary for sleep.

Available Doses and Dosage Forms:

Ramelteon is available in eight-milligram tablets for oral use. The suggested dose is eight milligrams, taken no later than 30 minutes before bedtime. The total daily dosage of Ramelteon should not exceed eight milligrams.

For Patients:

What Is Insomnia?

A frequent sleep disorder called insomnia is trouble getting to sleep, remaining asleep, or getting high-quality sleep, even when rest is encouraged. It may disrupt regular activities and result in drowsiness during the day. Short-term insomnia usually lasts a few days or weeks and is frequently brought on by stress or changes in routine or environment. When chronic insomnia lasts for more than three months and happens no less than three nights a week, no other medical condition is a suitable explanation for it. In addition to raising the risk of high blood pressure, coronary heart disease, diabetes, and cancer, insomnia can impede memory and attention.

Healthcare professionals may ask about sleep habits and suggest maintaining a sleep diary to detect insomnia. Good sleep habits, medicine, and cognitive behavioral therapy may be used to treat insomnia.

How Is Ramelteon Administered?

Ramelteon comes in tablet form. It is taken orally once daily, ideally no later than 30 minutes before bed. Taking it with food or right away after eating is not advised. It is important to take Ramelteon exactly as directed without changing the dosage or frequency. The tablets should not be broken up, chewed, or crushed; they must be swallowed whole.

Patients who take Ramelteon may experience rapid sleepiness. They should finish making last-minute preparations and head straight to bed, refraining from engaging in other activities. It should only be taken if the patient can stay awake within seven to eight hours after taking Ramelteon.

After beginning Ramelteon medication, insomnia should become better in seven to ten days. Patients should get in touch with their doctor if their insomnia does not get better throughout this time or if it gets worse at any point.

What Are the Things to Inform the Doctor Before Taking Ramelteon?

• If a patient has an allergy to Ramelteon, any other drug, or any of the substances in Ramelteon tablets, they should notify their doctor and pharmacist.

• Patients should also discuss any Fluvoxamine they may take, as this medication may interfere with Ramelteon.

• A list of all the vitamins, supplements, prescription and over-the-counter drugs, herbal remedies, and vitamins the patient intends to take should also be provided. This covers drugs including Rifampin, sedatives, other sleeping pills, Ticlopidine, antifungals, Cimetidine, fluoroquinolones, HIV protease inhibitors, anxiety or painkillers, and tranquilizers.

• Patients should let their doctor know if they have ever tried suicide or had suicidal thoughts. They should also let them know if they have ever had sleep apnea (a condition where a person frequently stops breathing for a brief time during the night), depression, mental illness, liver disease, or chronic obstructive pulmonary disease (COPD- breathing difficulties caused by lung damage).

• Patients should let their doctor know if they become pregnant while taking Ramelteon and reveal if they are nursing a baby, intend to get pregnant, or are already pregnant.

Dietary Instructions:

Patients must contact their doctor if they plan to drink grapefruit juice while on this medication.

Missed Dose:

It is best to take Ramelteon only at night. A missed dose may be taken later, but only if the patient can remain in bed for seven to eight hours after its consumption and is having trouble falling asleep. It should only be taken if the person is ready to sleep for that long.

Overdose:

It is advised to use general symptomatic and supportive measures in the event of a possible overdose of Ramelteon, including immediate stomach lavage when considered suitable. Fluids should be injected intravenously (through the vein) when needed. Monitoring vital signs, including blood pressure, respiration, pulse, and other relevant indicators, is crucial. Hemodialysis (filtering of water and waste from the blood) is not a suitable treatment for overdose, though, because it is ineffective in lowering exposure to Ramelteon. Healthcare professionals may get the most recent information on managing overdoses by contacting a poison control center and taking into account the possibility of multiple drug intake in cases of suspected overdose.

Storage:

Ramelteon should be stored at room temperature, away from extreme heat and moisture, and in its original, safely closed container. It should also be kept out of children's reach and not kept in the bathroom. Since many medicine containers are not child-resistant and easily opened, all medications must be kept out of children's sight.

Side Effects:

• It is recommended that patients notify their healthcare physician as soon as possible if they feel tired, sleepy, or lightheaded.

• Swelling of the tongue or throat, trouble breathing or swallowing, and feeling of throat closure symptoms should be treated immediately.

• A decrease in libido, vomiting, irregular menstruation cycles, milky discharge from the nipples, nausea, and problems with reproduction are among the other severe adverse effects.

• Ramelteon may result in daytime drowsiness. Therefore, patients should avoid using machinery or driving until they are familiar with its side effects. Alcohol should be avoided while taking Ramelteon.

• Patients can exhibit abnormal behavior, such as driving or cooking food while partially asleep. If such behaviors occur, patients should contact their doctor immediately.

• Patients should keep an eye out for any changes in their mental state while taking Ramelteon, including agitation, anxiety, hallucinations, memory issues, new or worsening depression, thoughts of suicide, or strange mood or behavior swings. Families should be aware of these signs to get assistance when necessary.

For Doctors:

Indication:

Ramelteon is indicated for the treatment of insomnia, specifically for individuals experiencing difficulty with sleep onset.

Contraindication:

It is not recommended to give Ramelteon to patients again if they experience angioedema after receiving treatment. Moreover, taking Ramelteon together with Fluvoxamine is not advised.

What Are the Pharmacological Aspects of Ramelteon?

• Mechanism of Action - Ramelteon functions as an activator of the melatonin receptor (MT), showing little selectivity for MT3 receptors while having a high affinity for MT1 and MT2 receptors. Sleepiness and the desire to sleep are enhanced by melatonin, which is naturally elevated at night. MT2 receptors regulate the body's internal clock, while MT1 receptors aid in controlling drowsiness and encouraging sleep. In contrast to MT1 and MT2, MT3 receptors have no connection to the sleep-wake cycle. Other receptors important in sleep, including those for neurotransmitters like dopamine and serotonin, cytokines, neuropeptides, and GABA (gamma-aminobutyric acid), are not affected by Ramelteon.

• Pharmacokinetics - At least 84 percent of the administered dose of Ramelteon is absorbed into the systemic circulation, indicating fast and widespread absorption. Its volume of distribution, which represents how it is distributed throughout the body, is roughly 73.6 liters. About 82 percent of the medications bind to proteins in human serum, indicating a moderate level of protein binding. After taking the medication orally, most of it is removed by the kidneys, where 84 percent is eliminated in urine, and the remaining four percent is expelled in feces. Less than 0.1 percent of the supplied dose is eliminated in urine and feces in its unmodified form, indicating little excretion of the parent chemical. Ramelteon should not be taken along with a high-fat meal.

Clinical Studies:

For five weeks, long-term Ramelteon treatment for adults with chronic insomnia consistently reduced latency to persistent sleep (LPS) without producing clinically significant changes in sleep architecture, residual pharmacologic effects the following morning, rebound insomnia, or withdrawal symptoms upon cessation. There were no quantifiable variations between the two Ramelteon dosages.

Drug Interactions:

Ramelteon should not be used with drugs like Zolpidem, Donepezil, Fluconazole (strong CYP2C9 inhibitor), Donepezil, Rifampin (strong CYP enzyme inducer), Fluvoxamine (strong CYP1A2 inhibitor), and Ketoconazole (strong CYP3A4 inhibitor).

Warnings and Precautions:

• Severe Anaphylactic and Anaphylactoid Reactions - After using Ramelteon, some individuals experienced rare incidences of angioedema, some of which occurred after the first dose and included potentially fatal symptoms like swelling of the tongue, glottis, or larynx. Some symptoms, like breathing difficulties, constriction in the throat, or nausea, can be mistaken for anaphylaxis. Serious cases that highlighted the possibility of airway obstruction and deadly consequences required rapid medical intervention. Patients who use Ramelteon and develop angioedema should stop using the medication and refrain from using it again.

• Comorbidity Diagnosis - Before starting Ramelteon for insomnia, it is critical to thoroughly assess the patient for any underlying medical issues contributing to their sleep issues. If insomnia persists after seven to ten days of starting the treatment, it may be a sign of an underlying condition that requires medical attention. Additional testing should be done if the sleeplessness worsens or new behavioral or cognitive problems appear. These signs may potentially point to an underlying issue. During clinical trials, Ramelteon has been linked to cognitive and behavioral issues as well as sleeplessness that gets worse.

• Abnormal Thought and Behavior Patterns - Ramelteon may alter one's thoughts and actions. It may exacerbate depression in depressed individuals or possibly trigger suicidal thoughts or behaviors. Hallucinations, odd behavior, agitation, or excessive enthusiasm (mania) have been reported by some users. Unexpected occurrences of anxiety, memory loss, and other mental problems are also possible. After taking Ramelteon, some people fell asleep and went on to do things like drive, cook, or have sex without remembering it afterward. These behaviors may be more likely in those who have used central nervous system (CNS) depressants or who drink alcohol. These effects can occur in people who have never taken hypnotics before. It is highly recommended that someone on Ramelteon quit taking the drug if they exhibit any of these abnormal sleep behaviors.

• Reproductive Effects - Adult reproductive hormone changes associated with Ramelteon include decreased testosterone and increased prolactin levels. It is still unknown how using Ramelteon on an intermittent or long-term basis will affect a person's reproductive system.

• Central Nervous System Effects - People should avoid doing tasks requiring focus after taking Ramelteon, such as operating heavy machinery or driving. They should restrict their activities to those required to get ready for bed. They should also abstain from drinking alcohol while using Ramelteon since doing so could intensify the effects of both drugs.

• Concomitant Disease - The use of Ramelteon is not recommended in those with severe sleep apnea as it has not been studied in this population. Likewise, Ramelteon should not be used by anyone with a significant liver impairment.

Specific Considerations:

• Pregnancy - According to post marketing data, using Ramelteon during pregnancy has not been linked to an increased risk of serious birth abnormalities, miscarriage, or adverse outcomes for moms of newborns. However, at levels far higher than the advised human dose, animal research on rats revealed developmental problems, including birth abnormalities.

• Lactation - The presence of Ramelteon or its metabolites in human milk and information regarding its effects on nursing infants or milk production is unknown. Ramelteon's mechanism of action may make breastfed infants drowsy. The advantages of nursing should be evaluated against the mother's need for the medication and any possible hazards to the child when deciding whether to use Ramelteon. Mothers using Ramelteon should monitor their infants for signs of drowsiness and feeding issues if they are exposed to breast milk. To minimize the infant's exposure, mothers may consider stopping breastfeeding and discarding their milk during treatment and for 25 hours after taking Ramelteon.

• Pediatric Patients - It is unknown if Ramelteon is safe and effective for pediatric patients.

• Geriatric Patients - Data from clinical trials showed that there were no general variations in safety or efficacy between individuals who were older and subjects who were younger. A trial involving 33 older patients with insomnia was double-blind, randomized, and placebo-controlled. It assessed how a single dose of Ramelteon affected their ability to move, balance, and remember things after waking up in the middle of the night. Comparing Ramelteon eight mg at night against a placebo, the study discovered no impairment in these functions. However, this study needs to provide more information to determine the effects on senior people's nighttime balance and address the consequences of multiple dosages.

• Chronic Obstructive Pulmonary Disorder (COPD) - According to the trials' findings, respiration was unaffected by a single dose of Ramelteon as determined by blood oxygen levels. The total effect of Ramelteon on breathing in patients with COPD is still unknown, though little research is available on the consequences of administering numerous doses of the medication.

• Sleep Apnea - A placebo and a 16 mg dosage of Ramelteon were compared. The sleep apnea assessments showed no statistically significant differences between the Ramelteon and placebo groups. The potential effects of taking numerous doses of Ramelteon on sleep apnea need to be better understood. Ramelteon is not advised for those who have severe obstructive sleep apnea because it has not been evaluated in this population.

• Liver Impairment - Ramelteon should be used carefully in patients with moderate liver problems, as the drug levels in their bodies can be more than ten times higher than normal. However, it is not recommended for those with severe liver problems.

• Kidney Impairment - The levels of the primary medication and its metabolite in the body are unaffected by Ramelteon in individuals with kidney impairment. Therefore, patients with renal impairment do not require a change in the dosage of Ramelteon.